Crossmark

Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trial

Crossref DOI link: https://doi.org/10.1038/s41392-025-02160-8

Published Online: 2025-02-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nie, Run-Cong

Yuan, Shu-Qiang

Ding, Ya

Chen, Yong-Ming

Li, Yuan-Fang

Liang, Cheng-Cai

Cai, Mu-Yan https://orcid.org/0000-0002-4646-4391
Chen, Guo-Ming

Wang, Wei

Sun, Xiao-Wei

Weng, De-Sheng

Li, Dan-Dan https://orcid.org/0000-0001-9346-3212
Zhao, Jing-Jing

Chen, Xiao-Jiang

Guan, Yuan-Xiang

Liu, Zhi-Min

Liang, Yao

Luo, Ma

Chi, Jun

Qiu, Hai-Bo

Zhou, Zhi-Wei

Zhang, Xiao-Shi

Chen, Ying-Bo
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82103586)

Chinese Society of Clinical Oncology (Y-HR2022MS-0324)
License Information

Text and Data Mining valid from 2025-02-05

Version of Record valid from 2025-02-05
More Information

Article History

Received: 30 July 2024

Revised: 20 January 2025

Accepted: 23 January 2025

First Online: 5 February 2025

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below